Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma
NCT04230759Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Countries
- 3
- Sponsor
- Goethe University Frankfurt
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Drugs
- durvalumab
- Conditions
- anal squamous cell carcinoma (SCCA)
01
Overview
Phase 2, randomised trial of durvalumab in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Disease-Free Survival at 3 years. Started Jan 2020; status: active, not recruiting.
02
Design
2 arms- Study design
- Randomized
5FU+Mitomycin C
Standard radiochemotherapy (5-FU + Mitomycin C + Radiation)
5FU+Mitomycin C+Durvalumab
Standard radiochemotherapy + Durvalumab
03
Who it enrols
Adult patients with locally-advanced (Stage IIB-IIIC) anal squamous cell carcinoma, ECOG 0-1, adequate organ function, and no prior treatment with PD-1/PD-L1 inhibitors.
04
Endpoints
Primary
Disease-Free Survival
Secondary
Major Adverse Events
Clinical Complete Response
Overall Survival
Colostomy-Free Survival
Cumulative Incidence of Locoregional Recurrence
Cumulative Incidence of Distant Recurrence
Quality of Life
Beyond the preview
Go deeper on NCT04230759.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230759.